Trial Profile
Randomized Trial of a Switch to a Kaletra + Current Dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) Backbone Versus Continuation of the Current Regimen in Patients With Poor Immune Responses to Highly Active Antiretroviral Therapy (HAART) in Patients With Complete Viral Suppression: A Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- 26 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2008 Status changed from recruiting to in progress.
- 17 Nov 2005 New trial record.